KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$72.0 million.

  • Xenon Pharmaceuticals' Free Cash Flow fell 4333.5% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.3 million, marking a year-over-year decrease of 5371.63%. This contributed to the annual value of -$184.5 million for FY2024, which is 1769.62% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Free Cash Flow stood at -$72.0 million for Q3 2025, which was down 4333.5% from -$64.4 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Free Cash Flow's 5-year high stood at -$14.0 million during Q2 2021, with a 5-year trough of -$72.0 million in Q3 2025.
  • For the 5-year period, Xenon Pharmaceuticals' Free Cash Flow averaged around -$37.6 million, with its median value being -$35.5 million (2023).
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 1170.9% in 2022, then tumbled by 10304.39% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Free Cash Flow stood at -$21.2 million in 2021, then plummeted by 74.72% to -$37.1 million in 2022, then increased by 4.32% to -$35.5 million in 2023, then tumbled by 55.49% to -$55.2 million in 2024, then tumbled by 30.57% to -$72.0 million in 2025.
  • Its last three reported values are -$72.0 million in Q3 2025, -$64.4 million for Q2 2025, and -$61.7 million during Q1 2025.